IQVIA Holdings Inc. $IQV Shares Sold by Community Trust & Investment Co.

Community Trust & Investment Co. trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 13.8% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 79,885 shares of the medical research company’s stock after selling 12,783 shares during the quarter. IQVIA comprises approximately 1.0% of Community Trust & Investment Co.’s portfolio, making the stock its 27th biggest position. Community Trust & Investment Co.’s holdings in IQVIA were worth $21,477,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Apella Capital LLC raised its holdings in IQVIA by 4.7% in the 3rd quarter. Apella Capital LLC now owns 1,235 shares of the medical research company’s stock worth $319,000 after purchasing an additional 55 shares during the period. Breakwater Capital Group grew its position in shares of IQVIA by 3.2% during the second quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock worth $401,000 after purchasing an additional 64 shares in the last quarter. Fortitude Family Office LLC increased its holdings in shares of IQVIA by 17.2% in the third quarter. Fortitude Family Office LLC now owns 443 shares of the medical research company’s stock worth $119,000 after purchasing an additional 65 shares during the last quarter. First Growth Capital LLC grew its holdings in IQVIA by 3.2% during the 1st quarter. First Growth Capital LLC now owns 2,173 shares of the medical research company’s stock valued at $375,000 after buying an additional 68 shares in the last quarter. Finally, Chicago Partners Investment Group LLC grew its holdings in shares of IQVIA by 1.5% in the first quarter. Chicago Partners Investment Group LLC now owns 4,635 shares of the medical research company’s stock valued at $812,000 after purchasing an additional 70 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of IQVIA stock opened at $270.80 on Friday. The business has a 50-day moving average price of $260.18 and a 200 day moving average price of $212.46. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $277.40. The firm has a market cap of $44.57 billion, a PE ratio of 33.60, a P/E/G ratio of 2.27 and a beta of 1.17. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. IQVIA’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period last year, the company posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts predict that IQVIA Holdings Inc. will post 11.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of recent research reports. JPMorgan Chase & Co. lifted their target price on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Stifel Nicolaus lifted their price objective on shares of IQVIA from $276.00 to $303.00 and gave the company a “buy” rating in a report on Wednesday. William Blair raised IQVIA to a “strong-buy” rating in a research note on Tuesday, July 28th. TD Cowen increased their price target on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Finally, Royal Bank Of Canada boosted their price objective on shares of IQVIA from $247.00 to $319.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 29th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $276.00.

Insider Buying and Selling

In other news, insider W. Richard Staub sold 5,500 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the transaction, the insider directly owned 13,312 shares in the company, valued at $3,097,436.16. This trade represents a 29.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider James G. Berkshire sold 2,668 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the transaction, the insider directly owned 10,890 shares of the company’s stock, valued at $2,845,883.70. This represents a 19.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 15,581 shares of company stock valued at $3,796,021. 1.70% of the stock is currently owned by company insiders.

IQVIA Profile

IQVIA Holdings Inc (NYSE: IQV) is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA’s offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.